Phytomedicine : international journal of phytotherapy and phytopharmacology · 2025
Guanxinning tablets plus aspirin versus aspirin monotherapy to reduce cardiovascular events after percutaneous coronary intervention: A cluster-randomized controlled trial (GAP trial).
СтатьяРандомизированное исследованиеМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xu Hao, Li Jingen, Zhao Yang, Chen Zhuo, Kantas Dimitrios, Zhang Guoyuan, Gao Rui, GAP trial group
Аннотация
BACKGROUND: Prolonged dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) lowers thrombotic risk but increases bleeding, creating a therapeutic dilemma. Guanxinning tablets (GXNT), a traditional Chinese medicine with antithrombotic and cardioprotective effects, may offer an alternative strategy.
PURPOSE: To evaluate whether GXNT combined with aspirin reduces cardiovascular events without increasing bleeding in patients transitioning from DAPT to aspirin monotherapy after PCI.
STUDY DESIGN: An open-label, cluster-randomized controlled trial conducted in 63 tertiary hospitals in China between March 2017 and December 2018.
METHODS: A total of 3586 patients with coronary heart disease (CHD) who had completed at least 12 months of DAPT following PCI were enrolled. Hospitals and participants were randomized in a 2:1 ratio to receive GXNT plus aspirin or aspirin alone for 12 months, followed by 12 months of additional follow-up. The primary endpoint was a composite of cardiovascular death, non-fatal myocardial infarction, stent thrombosis, revascularization, ischemic stroke, and rehospitalization for unstable angina. Outcome assessors and data analysts were blinded to treatment allocation. The intention-to-treat analysis principle was adopted, and ICC were accounted for in the statistical analysis.
RESULTS: Of the participants, 2389 received GXNT plus aspirin and 1197 received aspirin alone. After a median follow-up of 23 months, GXNT significantly reduced the primary outcome (11.0 % vs. 13.2 %; adjusted hazard ratio [HR] 0.79, 95 % confidence interval [CI] 0.63-0.98). Rates of revascularization (3.8 % vs 4.7 %) and rehospitalization for unstable angina (7.0 % vs 9.7 %) were also lower in the GXNT group. Major bleeding events were rare and similar across groups.
CONCLUSION: GXNT combined with aspirin reduced adverse cardiovascular events after PCI without increasing bleeding, supporting its potential as an alternative to prolonged DAPT.
PURPOSE: To evaluate whether GXNT combined with aspirin reduces cardiovascular events without increasing bleeding in patients transitioning from DAPT to aspirin monotherapy after PCI.
STUDY DESIGN: An open-label, cluster-randomized controlled trial conducted in 63 tertiary hospitals in China between March 2017 and December 2018.
METHODS: A total of 3586 patients with coronary heart disease (CHD) who had completed at least 12 months of DAPT following PCI were enrolled. Hospitals and participants were randomized in a 2:1 ratio to receive GXNT plus aspirin or aspirin alone for 12 months, followed by 12 months of additional follow-up. The primary endpoint was a composite of cardiovascular death, non-fatal myocardial infarction, stent thrombosis, revascularization, ischemic stroke, and rehospitalization for unstable angina. Outcome assessors and data analysts were blinded to treatment allocation. The intention-to-treat analysis principle was adopted, and ICC were accounted for in the statistical analysis.
RESULTS: Of the participants, 2389 received GXNT plus aspirin and 1197 received aspirin alone. After a median follow-up of 23 months, GXNT significantly reduced the primary outcome (11.0 % vs. 13.2 %; adjusted hazard ratio [HR] 0.79, 95 % confidence interval [CI] 0.63-0.98). Rates of revascularization (3.8 % vs 4.7 %) and rehospitalization for unstable angina (7.0 % vs 9.7 %) were also lower in the GXNT group. Major bleeding events were rare and similar across groups.
CONCLUSION: GXNT combined with aspirin reduced adverse cardiovascular events after PCI without increasing bleeding, supporting its potential as an alternative to prolonged DAPT.